

CEPI Newsletter

[View this email in your browser](#)

CEPI | New vaccines for a safer world

Coalition for Epidemic Preparedness Innovations

Newsletter 10 March 2017

Message from the Interim CEPI CEO

When the deadline for CEPI's first call for proposals passed 8 March, we counted more than 30 submitted proposals. The applications come from many parts of the world and a wide range of partners. We are encouraged by this diversity and extent of interest, which gives CEPI several options to progress candidates into phase II trials by end of 2021.

This is a significant step for CEPI and means we have started the core part of our work for real. CEPI will be launching other calls later this year, and the response we have on this first call is highly encouraging.

John-Arne Røttingen, Interim CEPI CEO

More than 30 applications for CEPI's first call

CEPI received more than 30 applications for our first call for development of vaccines against Lassa, MERS-COV and Nipah, which had deadline 8 March. The applications will now be evaluated, and shortlisted applicants will be invited to submit full proposals in April 2017.

The partner organizations represented among the applicants are from North America, Europe, Africa, the Middle East, South-East Asia and Australia, representing academic institutions, biotechs, large pharmaceutical companies and Product Development Partnerships. There was also a broad diversity displayed in the vaccine platform technologies being used, including novel concepts.



Access to Vaccines Index 2017

The Access to Vaccines Index 2017 was published earlier this month by the Access to Medicines Foundation. This is the first landscape analysis to evaluate how vaccine companies are improving immunisation coverage. It comprises a baseline measurement on the steps companies are taking in this area, and the mechanisms triggering them to join global efforts to increase access to vaccines. The report recognizes and highlights CEPI as an important new global mechanism to fund and facilitate the development of new vaccines against emerging infectious diseases, and encourages vaccine companies to engage actively with CEPI and other preparedness mechanisms to ensure their vaccine R&D expertise results in global benefits. The Access to Vaccines Index 2017 can be found [here](#).

Updates

Most of the power point presentations from the Scientific Community Meeting are now published on the CEPI website. You will find the pdfs [here](#).

Please note that the e-mail address apply@cepi.net is no longer active. Please use info@cepi.net.

www.cepi.net

info@cepi.net